Skip to content
See the World Through ScienceA project of ALLATRA

FDA Rejects a Duchenne Cell Therapy, Saying Its Trial Data Cannot Be Trusted

Science

Republish this story

Our work is licensed under Creative Commons BY-NC 4.0. You may republish this piece for free — with credit to ALLATRA Media and a link to the original, unedited beyond length trims, and not for commercial use.

Read the full license

Light micrograph of a muscle biopsy from a person with Duchenne muscular dystrophy, showing scattered dark pink muscle fibers separated by pale fat and connective tissue.
In Duchenne muscular dystrophy, fat and connective tissue take over the space where muscle fibers should be. Deramiocel, the cell therapy the FDA turned down, was tested in boys and young men with the disease (illustrative)."Duchenne-muscular-dystrophy" by Dr. Edwin P. Ewing, Jr., via Wikimedia Commons, Public domain

The U.S. Food and Drug Administration has refused to license deramiocel, an experimental cell therapy for Duchenne muscular dystrophy, telling its developer that the trial meant to support the application produced data the agency cannot rely on. The FDA issued a complete response letter to Capricor Therapeutics on Nov. 20, 2026, and said the correspondence identifies serious data integrity violations in the conduct of the HOPE-3 study that cannot be remediated after the fact.

Deramiocel is an allogeneic cardiosphere-derived cell therapy, grown from donor heart tissue, and Capricor had asked the agency to license it for Duchenne muscular dystrophy, a rare inherited disease that progressively weakens muscle. A complete response letter is the agency's refusal of an application — the product cannot be approved as it stands.

The FDA's statement says its Bioresearch Monitoring program inspected Capricor in connection with the application and found serious deficiencies in how HOPE-3 was conducted. The deficiencies include "unauthorized post hoc changes to the statistical analysis plan; violations of study blinding procedures; and additional protocol violations" that, individually and collectively, compromise the reliability of the study data. Even if the question of clinical benefit could be settled, the agency's position is that data of this kind cannot be a reliable foundation for an approval decision.

HOPE-3 had also missed the main and secondary goals set before it began: upper limb function and cardiac imaging measures. The agency said the data integrity problems amplified its concerns about that failure.

Capricor had filed a major amendment to the application after a public meeting of the FDA's Cellular, Tissue, and Gene Therapy Advisory Committee on July 29, 2026, adding 24-month results from an open-label extension of HOPE-3 and changing the indication it was seeking from cardiomyopathy in Duchenne patients to upper limb impairment. The agency reviewed that additional evidence and still found the standard for approval unmet.

According to the statement, the FDA approaches rare disease applications intending to find a path forward, but "flexibility in regulatory approach cannot come at the cost of the foundational requirement that the data underlying an approval decision be reliable."

The agency also issued a Regulatory Responsibility Letter dated Nov. 20, 2026, covering the inspection findings, and Capricor will have the opportunity to address the issues it raises.

Sources

Medical Disclaimer: This content is provided for general informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition, concern, symptom, or treatment decision.

Spot an error?

Spot an error?

Report an error

Spotted a mistake on this page? Tell us what's wrong and our editors will take a look.

What kind of problem?

Only if you'd like us to be able to follow up. We won't use it for anything else.

We correct mistakes openly. Select any text to flag it. Fixes are logged under our Corrections Policy.

Report an error

Reporting on

FDA Rejects a Duchenne Cell Therapy, Saying Its Trial Data Cannot Be Trusted

What kind of problem?

Only if you'd like us to be able to follow up. We won't use it for anything else.

We read every report. Corrections are logged publicly.